| Immunocore reports third quarter financial results and provides a business update | 11/06 07:00 | globenewswire.com |
| Immunocore (IMCR) Upgraded to Buy: Here's Why | 11/05 13:00 | zacks.com |
| Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer | 09/14 03:00 | globenewswire.com |
| Immunocore to present at the 2024 Cantor Global Healthcare Conference | 09/12 16:05 | globenewswire.com |
| Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak | 08/30 11:40 | seekingalpha.com |
| Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal | 08/12 04:12 | seekingalpha.com |
| Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript | 08/11 06:53 | seekingalpha.com |
| 3 Small-Cap Stocks with Significant Growth Potential | 08/06 10:41 | investorplace.com |
| Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response | 06/01 08:00 | globenewswire.com |
| Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 | 05/31 16:05 | globenewswire.com |